Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 2/20 | 0.40 |
| ▸ | ORAI1 | Q96D31 | 2/20 | 0.40 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17045200 | 0.94 | STIM1 (0.42) | STIM1ORAI1ADORA3ADORA2AADORA1 | |
| SCHEMBL17045197 | 0.88 | STIM1 (0.51) | STIM1ORAI1 | |
| SCHEMBL16463680 | 0.81 | STIM1 (0.43) | STIM1ORAI1ADORA3ADORA2AADORA1 | |
| SCHEMBL17045187 | 0.81 | STIM1 (0.54) | STIM1ORAI1 | |
| SCHEMBL17045188 | 0.79 | STIM1 (0.50) | STIM1ORAI1 | |
| SCHEMBL16464984 | 0.76 | STIM1 (0.49) | STIM1ORAI1ADORA3ADORA2AADORA1 | |
| SCHEMBL16463664 | 0.70 | STIM1 (0.52) | STIM1ORAI1 | |
| SCHEMBL1702011 | 0.64 | STIM1 (0.43) | STIM1ORAI1ADORA2AADORA1SCN9A | |
| SCHEMBL16636703 | 0.64 | STIM1 (0.41) | STIM1ORAI1SCN9A | |
| SCHEMBL16465852 | 0.63 | STIM1 (0.62) | STIM1ORAI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9512116-B2 | Compounds that modulate intracellular calcium | CALCIMEDICA, INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2015-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246909-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ADORA3 2617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.